**K⁺ channel opening: a new drug principle in cardiovascular medicine**

Jens Erik Nielsen-Kudsk, Søren Boesgaard, Jan Aldershivle

Many drugs used in cardiology act by changing the gating properties of ion channels. This is true for Ca²⁺ antagonists which are blockers of voltage-operated L-type Ca²⁺ channels and for most antiarrhythmics. Class I agents are blockers of Na⁺ channels whereas class III antiarrhythmics prolong the cardiac action potential by blockade of K⁺ channels. In the past decade much has been learnt about the physiology and pharmacology of ion channels.

Pharmacological agents that selectively open K⁺ channels have been developed and this novel group of drugs is rapidly expanding. K⁺ channel openers are peripheral and coronary vasodilators but they additionally act on the myocardium and seem to protect it from damage during ischaemia and reperfusion.

The purpose of this paper is to review some of the pharmacology of cardiovascular K⁺ channels and to elucidate the potential clinical value of K⁺ channel opening as a new concept in cardiovascular medicine.

**Basic aspects of K⁺ channels**

K⁺ channels play a key role in the regulation of membrane potential and cell excitability and the function of these channels contributes to the electrical and mechanical properties of the heart and vasculature. The concentration of K⁺ inside cells (150 mM) is much higher than outside (3-5 mM) due to the action of the Na⁺/K⁺ pump. Opening of K⁺ channels makes K⁺ ions flow out of the cell along the outward directed electrochemical gradient for K⁺. This changes the membrane potential in a hyperpolarising direction. It becomes more negative and is moved towards the K⁺ equilibrium potential. In contrast, blockade of K⁺ channels shifts the membrane potential in a depolarising direction. In the heart, repolarisation of the cardiac action potential is largely caused by opening of K⁺ channels. Membrane depolarisation and hyperpolarisation through blockade and opening of K⁺ channels are also important mechanisms regulating vascular smooth muscle contraction and relaxation.

**Diversity of K⁺ channels**

K⁺ channels are the most heterogeneous of all ion channels. So far at least 16 major types of K⁺ channels have been characterised and several subtypes exist within each major type of K⁺ channel. Each type of K⁺ channel serves a distinct function and the expression of K⁺ channels differs among tissues and organs. This high degree of diversity opens the fascinating possibility that pharmacologically selective openers or blockers of a specific K⁺ channel subtype may be developed to modulate specialised tissue functions. Identification of the different types of K⁺ channels have been made possible largely because of the development of the electrophysiological patch-clamp method which allows ion channels to be investigated at a single channel level. By this method it is possible to determine factors which open and close a channel (the gating properties) as well as the single channel conductance which is a measure of how easily ions flow through a channel (measured in pico Siemens). These variables are used to characterise and classify specific types of K⁺ channels. K⁺ channels can be divided into three major classes on basis of their gating properties: those that are gated by ligands such as ATP, Ca²⁺, neurotransmitters or G-proteins (ligand gated), those gated by changes in membrane potential (voltage gated) and those gated both by ligands and voltage. The voltage-gated K⁺ channels can be subdivided into outward or delayed rectifiers which are activated by cell membrane depolarisation and inward rectifiers which are closed by depolarisation.

Several K⁺ channels have now been cloned thus allowing the molecular and structural basis of the diversity of K⁺ channels to be determined. On the basis of molecular structure two major super-families of K⁺ channels can be discriminated. The S4 superfamily (fig 1), to which voltage-gated delayed rectifier K⁺ channels belong, is built up of large protein subunits of six membrane-spanning α-helical segments (S1–S6) and a seventh hairpin-shaped segment interposed between S5 and S6. The seventh segment forms a major part of the K⁺ channel pore itself (P-region) while S4 is believed to be the voltage sensor. K⁺ channels are tetramers formed by four subunits. Several different genes code for different K⁺ channel subunits and these assemble as heteromultimers, resulting in an enormous diversity. The inward rectifier K⁺ channel superfamily (fig 1) is characterised by subunits composed of only two membrane spanning segments (M1 and...
Figure 1  The presumed structure of K′ channel subunits belonging to the S4 superfamily (upper) and the inward rectifier superfamily (lower) of K′ channels.

M2). The pore region is shaped like a hairpin and is almost identical to that of the S4 superfamily.

CARDIOVASCULAR K′ CHANNELS

The most important cardiovascular K′ channels are listed in table 1. The outward rectifier or delayed rectifier (Kw) channel is activated by membrane depolarisation and gives rise to an outward directed K′ current which is responsible for repolarisation of the cardiac action potential. It can be blocked by class III antiarrhythmic agents. The inward rectifier (Kw) keeps the resting membrane potential stable during cardiac diastole. It is open at the resting membrane potential but closes during depolarisation. This type of channel is sparse in conduction tissue that undergoes spontaneous depolarisation in diastole. The acetylcholine activated K′ channel (Kw,ac) is activated by the binding of acetylcholine released from vagal nerve endings to muscarinic receptors in atrial and atrioventricular (AV) nodal tissue. This channel mediates bradycardia and the decrease in AV-nodal conduction produced by vagal stimulation. The large conductance Ca2+-activated K′ channel (BKca) acts as a negative feedback mechanism in vascular smooth muscle. It is activated when intracellular Ca2+ is increased by the action of vasoconstrictors and it limits depolarisation and excessive Ca2+ stimulation. The ATP-sensitive K′ channel (KATP) is inhibited by high intracellular ATP concentrations. It is the target K′ channel subtype for synthetic K′ channel openers and is considered below.

The ATP-sensitive K′ channel

The KATP channel was first identified in cardiac myocytes. It is believed to have a structure similar to the inward rectifying superfamily of K′ channels. This type of channel is inhibited by a high intracellular concentration of ATP and is closed under conditions of normal myocardial metabolism. The channel opens under conditions of myocardial ischaemia. Channel opening is stimulated by a fall in ATP concentration and by acidosis, lactate, adenosine, and nucleotide diphosphates such as ADP and GDP. These factors may act in concert to activate the channel during myocardial ischaemia. The consequence of KATP opening is increased K′ efflux, accelerated repolarisation, and thereby a shortening of the cardiac action potential. Shortening of the plateau phase reduces the time available for Ca2+ influx which causes a decline in contractile function in the ischaemic zone. These effects reduce the energy consumption, spare high energy phosphates, and limit Ca2+ overload and hence tend to prolong survival of the ischaemic tissue. In this way KATP seems to represent an endogenous protective mechanism against myocardial metabolic stress.

K′ channels have also been identified in

<table>
<thead>
<tr>
<th>Type</th>
<th>Class</th>
<th>Conductance (pS)</th>
<th>Factors which induce opening</th>
<th>Blockers</th>
<th>Structure</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>KATP (ATP sensitive)</td>
<td>Ligand gated</td>
<td>10-30</td>
<td>Decreased [ATP], increased [NDP], K′ channel openers—e.g., cromakalim, pinacidil, nicorandil, minoxidil sulphonate</td>
<td>High [ATP], glibenclamide, 5-hydroxydecanoate</td>
<td>IR</td>
<td>Hyperpolarisation during metabolic stress and hypoxia/ischaemia Bradycardia by vagus stimulation</td>
</tr>
<tr>
<td>Kw,ac (ACh activated)</td>
<td>Ligand gated</td>
<td>10-25</td>
<td>G-proteins through muscarinic receptor stimulation Depolarisation, specific openers not yet available</td>
<td>4-Aminopyridine S4</td>
<td></td>
<td>Repolarisation of cardiac action potential</td>
</tr>
<tr>
<td>Kw (delayed rectifier)</td>
<td>Voltage gated</td>
<td>5-15</td>
<td>Voltage gated 10-15 Hyperpolarisation</td>
<td>Depolarisation IR</td>
<td></td>
<td>Maintenance of resting potential</td>
</tr>
<tr>
<td>Kw (inward rectifier)</td>
<td>Voltage gated</td>
<td>10-15</td>
<td>Increased [Ca2+], depolarisation, specific openers not yet available</td>
<td>Charybodotoxin, iberotoxin, TEA (1 mM)</td>
<td>S4</td>
<td>Reduction of excitability when [Ca2+] rises</td>
</tr>
<tr>
<td>BKca (Ca2+ activated)</td>
<td>Ligand and voltage gated</td>
<td>100-150</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NDP, nucleotide diphosphates such as adenosine diphosphate (ADP), guanidine diphosphate (GDP), and uridine diphosphate (UDP); ACh, acetylcholine; IR and S4, inward rectifier and S4 superfamilies of K′ channels.
vascular smooth muscle. Like the cardiac $K_{ATP}$ this channel is inhibited by ATP and stimulated by nucleotide diphosphates. It opens under conditions of hypoxia and $K_{ATP}$ opening may be one of the principal mechanisms which underlie hypoxic coronary vasodilation. Figure 2 shows some of the important factors which gate the $K_{ATP}$ in myocardial and coronary vascular smooth muscle cells.

ENDOGENOUS MODULATION OF $K_{ATP}$
Adenosine opens $K_{ATP}$ both in cardiomyocytes and coronary vascular smooth muscle cells probably through a G-protein dependent mechanism triggered by adenosine receptor stimulation. Other endogenous vasodilators such as calcitonin gene regulated peptide (CGRP), vasoactive intestinal peptide (VIP), endothelium derived hyperpolarising factor (EDHF), and prostacyclin act in part through $K_{ATP}$ opening. Most recently it has been reported that nitric oxide (endothelium derived relaxing factor, EDRF) apart from its stimulating effect on guanylate cyclase directly activates $K^+$ channels of the BK$_{Ca}$ type. In cultured coronary artery smooth muscle cells the vasconstrictors angiotensin II and endothelin inhibit $K_{ATP}$, but the functional significance of these findings is not yet clear.

PHARMACOLOGICAL MODULATION OF $K_{ATP}$
The best known of the new $K_{ATP}$ channel opening drugs are cromakalim, levcromakalim (the active enantiomer of cromakalim), pinacidil, nicorandil, and aprikalim. The chemical structures of these compounds are quite different and they have been subdivided into different groups (table 2). The first agent recognised as a $K^+$ channel opener was nicorandil, which is now in clinical use as an antianginal drug. However, this drug also contains a nitrate moiety and has a nitrovasodilator action in addition to its ability to open $K^+$ channels. Cromakalim, which was developed as an arterial vasodilator, was the first specific synthetic $K^+$ channel opener. The mechanism of action of this drug was reported in 1986. Later, some of the classic vasodilator drugs such as minoxidil sulphate (the active metabolite of minoxidil) and diazoxide were found to act by $K^+$ channel opening. At present, all available synthetic $K^+$ channel openers seem to be openers of $K_{ATP}$. There have been attempts to develop openers of the BK$_{Ca}$ channel (SCA40 and NS1619) but these agents are not selective. However, it is likely that selective pharmacological modulators for specific $K^+$ channel subtypes will be developed in the future.

The oral antidiabetic sulfonylurea drugs are selective blockers of $K_{ATP}$ and glibenclamide is now used as an important pharmacological tool to detect actions produced by drugs or endogenous substances which involve $K_{ATP}$ opening. $K_{ATP}$ channels are also present in pancreatic islets where they are essential to the physiological regulation of insulin secretion. In this tissue the $K_{ATP}$ channels are open under conditions of normal blood glucose but close when the intracellular concentration of ATP is raised by increased concentrations of glucose. Closure of $K_{ATP}$ leads to islet cell depolarisation and insulin secretion. Glibenclamide and other sulfonylureas specifically block $K_{ATP}$ and in this way promote insulin secretion. Concentrations of glibenclamide in the nM range are sufficient to block pancreatic $K_{ATP}$ channels whereas $\mu$M concentrations are required to block cardiovascular $K_{ATP}$ channels. With the exception of diazoxide, very high concentrations of the $K^+$ channel openers are required to open pancreatic $K_{ATP}$ and inhibit insulin secretion. Diazoxide does not discriminate between cardiovascular and pancreatic $K_{ATP}$ channels and because of its hypoglycaemic action it is no longer in clinical use. Minoxidil sulphate which is another opener of cardiovascular $K_{Ca}$ channels, actually blocks pancreatic $K_{ATP}$. Thus $K_{ATP}$ is not a single distinct type of channel but rather a family of several $K_{ATP}$ subtypes with important tissue-dependent differences in sensitivity to pharmacological modulators.

**Effects of $K^+$ channel openers on the circulation**

**SYSTEMIC CIRCULATION**
K$^+$ channel opener drugs have been shown to relax isolated systemic arteries contracted by a wide range of vasoconstrictors. These drugs are 10–100 times more potent on vascular smooth muscle than on the non-ischaemic myocardium. A unique characteristic of these drugs is their ability to relax contractions induced by moderately raised extracellular $K^+$ concentrations (20–30 mM) but not those induced by high concentrations of $K^+$ in the 40–120 mM range. As the extracellular $K^+$ concentration is raised the electrochemical
gradient for K⁺ is reduced and as a consequence the K⁺ efflux produced by K⁺ channel opening becomes gradually diminished. The cellular events which lead to vasorelaxation are shown in fig 3. The vasodilatation produced both in vitro and in vivo by these drugs can be blocked by glibenclamide.¹⁴

The haemodynamic profile of K⁺ channel openers in various animal species and man is characteristic of potent arterial vasodilators.³ They cause reflex stimulation of the sympathetic nervous system and of the renin-angiotensin system. Even at doses which greatly reduce blood pressure these drugs do not have a significant cardiodepressant action.

PULMONARY CIRCULATION
Vasoconstriction in response to hypoxia is a unique property of pulmonary arteries. It constrains the hypoxic vasodilatation seen in coronary and systemic arteries. Pulmonary arteries depolarise during hypoxia and may even discharge action potentials.⁵ Evidence is accumulating that K⁺ channel blockade is a key event which links hypoxia to pulmonary vasoconstriction.⁶⁻⁷ Exactly which type of K⁺ channel is involved is not clear. K⁺ channel openers relax isolated pulmonary arteries and some of these drugs have more potent relaxant effects in pulmonary arteries than in systemic arteries.⁸⁻¹⁰ In addition they inhibit hypoxic pulmonary vasoconstriction in animals.¹¹ In a study of acute haemodynamics in patients with angina pectoris, cromakalim reduced pulmonary vascular resistance to the same extent as systemic vascular resistance.¹² Thus K⁺ channel openers have a direct pulmonary vasodilator action in addition to their effect on the systemic circulation.

Effects of K⁺ channel openers on the heart
CORONARY CIRCULATION
K_{ATP} channels seem to be important in regulating the coronary circulation. In isolated perfused guinea pig hearts the coronary vasodilatation induced by hypoxia and ischaemia was prevented by glibenclamide and mimicked by cromakalim, indicating that opening of K_{ATP} may be important in hypoxic and ischaemic coronary vasodilatation.¹³ The activation of K_{ATP} may result from a direct effect of hypoxia or ischaemia on coronary vascular smooth muscle cells,¹⁴ but also from adenosine released from the surrounding myocardium. In the dog coronary circulation glibenclamide reduced both the reactive hyperaemic response after a brief coronary occlusion¹⁵ and the autoregulatory vasodilatation in response to low perfusion pressure.¹⁶ In addition glibenclamide causes vasocostriction during basal coronary flow²⁶ suggesting that K_{ATP} may have several important regulatory actions in the coronary circulation.

Pharmacological openers of K_{ATP} are potent coronary vasodilators in vitro and in vivo. Regional haemodynamic studies have shown that these drugs preferentially produce coronary vasodilatation.¹⁷ The K⁺ channel opener aprikalim even produces coronary vasodilatation in doses that have no effect on blood pressure.¹⁸ In vitro these drugs produce coronary vasorelaxation when the endothelium is present or when it is removed. Cromakalim, pinacidil, and nicorandil dilate large epicardial coronary arteries as well as small coronary resistance arteries in vivo. However, damage of the endothelium by balloon angioplasty in dogs greatly reduced the dilatation of large coronary arteries by cromakalim and pinacidil whereas that produced by nicorandil was unaffected.¹⁹ Cromakalim and pinacidil therefore seem to dilate large coronary arteries in vivo partly by an endothelium-dependent mechanism possibly induced by an increase in proximal flow caused by dilatation of the small coronary resistance vessels. The endothelium-independent coronary vasodilatation of large coronary arteries produced by nicorandil is probably mediated by the additional nitrate action of the drug.

MYOCARDIUM
K⁺ channel openers only influence the function of the non-ischaemic myocardium at concentrations that are much higher than those required for vascular smooth muscle relaxation. At such high concentrations these drugs shorten cardiac action potential duration and depress cardiac contractility.¹⁵ However, at much lower concentrations these drugs exert cardioprotective actions, with some K_{ATP} openers acting at concentrations which produce only minimal haemodynamic effects.¹⁵ In globally ischaemic rat hearts, cromakalim and pinacidil improved the post-ischaemic recovery of contractile function and cro-
makalim additionally reduced lactate dehydrogenase release. At cardioprotective concentrations, the K⁺ channel openers did not influence the contractile function of non-ischaemic hearts. Several other K⁺,ATP openers have proved cardioprotective in isolated heart models. In experimental models of myocardial stunning, K⁺ channel openers markedly improved the recovery of myocardial function after ischaemia. In general these drugs are only cardioprotective when administered before reperfusion; they are ineffective if dosing is delayed and initiated during reperfusion. Also in animal models of myocardial infarction K⁺,ATP openers seem to be effective in reducing myocardial infarct size.

The precise mechanism underlying the cardioprotective effects of K⁺ channel openers is not yet clarified. Several studies have demonstrated that glibenclamide blocks the anti-ischaemic effects which therefore seem to be mediated by opening of K⁺,ATP. Another consequent finding is that cardioprotection can be achieved without coronary vasodilatation or dilatation of coronary collaterals, indicating that the effect is not dependent upon coronary vascular smooth muscle relaxation but involves a direct myocardial effect. This is further supported by the development of K⁺,ATP openers such as BMS-180448 that are selective for the ischaemic myocardium with a higher cardioprotective than vasorelaxant potency. The fact that these drugs have to be administered before reperfusion to be effective, indicates that they do not inhibit reperfusion injury directly but rather are protective during ischaemia itself. A mechanism that may account for the cardioprotective effect of K⁺,ATP openers is the accelerated shortening of cardiac action potential duration in early ischaemia caused by an enhanced K⁺ outward current. This would limit Ca⁺⁺ influx, counteract intracellular Ca⁺⁺ overload, enhance the decline of contractile function, and shorten the time to arrest of mechanical activity in the ischaemic zone of the myocardium. Such a cardioprotective mechanism would save energy and tend to prolong survival of the cardiomyocytes. Experiments have shown that cardioprotection by K⁺,ATP openers is associated with preservation of myocardial ATP. However, in recent studies in dogs with bimakalim and cromakalim there seemed to be some dissociation between action potential shortening and cardioprotection, indicating that additional mechanisms may be involved. During reperfusion after global ischaemia in rat hearts, cromakalim improved oxygen efficiency; this suggests a direct effect on cardiac metabolism, possibly at the level of the mitochondria.

Ischaemic preconditioning is a fascinating endogenous cardioprotective mechanism of the heart. In this phenomenon one or more brief periods of coronary occlusion markedly reduce the size of the myocardial infarction that follows a subsequent prolonged coronary artery occlusion. There is now substantial experimental evidence suggesting that ischaemic preconditioning is mediated partly or in whole by opening of K⁺,ATP. Gross and Auchampuch first showed that glibenclamide abolished the cardioprotective effect of preconditioning in dogs and that a K⁺,ATP opener cromakalim mimicked the effect of preconditioning without producing any systemic haemodynamic effects. Later studies in dogs and pigs supported an essential role for K⁺,ATP in preconditioning, whereas results of studies in rabbits and rats were somewhat conflicting. In a recent study by Yao and Gross, transient occlusion of the left anterior descending coronary artery (LAD) for only 3 min had no preconditioning effect. However, when bimakalim was given during the LAD occlusion period a significant preconditioning effect was seen. Bimakalim infusion alone did not influence infarct size, thus suggesting that pharmacological activation of K⁺,ATP can sensitise the myocardium to preconditioning. Glibenclamide also blocks preconditioning in man. In patients with angina pectoris, coronary angioplasty with two subsequent balloon inflations resulted in markedly reduced ST segment changes and pain during the second balloon inflation. The beneficial preconditioning effect of the first inflation was completely abolished by glibenclamide given in an oral dose used in antidiabetic treatment.

Previous studies have also suggested a role for adenosine in mediating ischaemic preconditioning. Adenosine acts through adenosine receptor stimulation in the myocardium and activates K⁺,ATP by a G-protein regulated mechanism. Thus it seems likely that K⁺,ATP opening is the mechanism whereby adenosine produces its protective effect. This is supported by the observation that glibenclamide in dogs completely blocked the ability of exogenously administered adenosine to mimic preconditioning.

**ELECTROPHYSIOLOGICAL ASPECTS**

Concern has been raised that K⁺ channel openers may possibly be proarrhythmic because of their ability to shorten cardiac action potential duration (APD), an effect that is expected to reduce cardiac refractoriness. However, shortening of cardiac APD may be both proarrhythmic and antiarrhythmic depending on the type of arrhythmia in question and the state of the myocardium. As a consequence there are experimental studies reporting proarrhythmic, not proarrhythmic, and antiarrhythmic effects with these drugs. In the non-ischaemic myocardium, only very high and clinically irrelevant concentrations produce shortening of APD and a tendency to arrhythmias. In contrast, clinically relevant concentrations inhibit arrhythmias induced by triggered activity (early and late afterdepolarisations) which are of relevance in the long QT syndrome and torsades de pointes. In patients with ischaemic myocardium, which favours reentry arrhythmias, these drugs shorten cardiac APD at clinically relevant concentrations and may facilitate arrhythmias. Whereas several studies have shown no proarrhythmia or even antiar-
rythmic activity of K+ channel openers in animal models of ischaemia-induced arrhythmias others have shown that proarrhythmic properties may be a risk particularly at the high concentrations that produce profound hypotension. In this context, K+ channel openers by their cardioprotective action may produce indirect antiarrhythmic effects in myocardial ischaemia. To date, pinacidil and nicorandil have been given to thousands of patients without reports of adverse arrhythmias. If the cardioprotective effect can be separated from the ability of these drugs to shorten cardiac APD, and some observations have suggested that they can, it should be possible to develop cardioprotective K+ opener of potential interest in the treatment of angina pectoris. In addition, these vasorelaxant drugs preferentially produce coronary vasodilation, some of them even without systemic haemodynamic changes. Their ability to inhibit myocardial stunning, limit myocardial infarct size, and mimic ischaemic preconditioning may further stimulate the interest in these drugs in coronary artery disease. However, although clinical trials have been initiated, there are currently no clinical data on pure K+ channel openers in patients with ischaemic heart disease.

Clinical data are available for nicorandil, which is now in clinical use as an antianginal agent. Although it is classified as a K+ channel opener it is not a pure one, but a hybrid between a nitrate and a KATP opener. Nicorandil has proved effective for the treatment of stable angina pectoris in placebo controlled clinical trials, and in comparative studies it shows the same degree of antianginal efficacy as nitrates, Ca2+ antagonists, and β adrenoceptor blockers. In addition, clinical data indicate that it might be useful in the treatment of unstable angina and variant angina.

Nicorandil dilates large coronary arteries and has balanced preload and afterload reducing effects because of its nitrate and KATP opener components, respectively. It increases cardiac output by haemodynamic changes and may be used in patients with poor left ventricular function. Interestingly nicorandil, unlike the nitrates, does not seem to induce the development of tolerance.

CARDIOPROTECTION

The cardioprotective effect of KATP openers is a most fascinating aspect of these new drugs. It implies that they may be able not only to prevent and relieve the symptoms of myocardial ischaemia but also to reduce some of the important consequences of myocardial ischaemia such as myocardial stunning and infarction. If this holds true in clinical practice, it is likely that these drugs will be of long-term benefit and reduce mortality in patients with ischaemic heart disease. These drugs may also have a therapeutic potential as adjunctive treatment in coronary angioplasty and coronary bypass surgery to protect the myocardium from ischaemic injury and to inhibit postoperative myocardial stunning.

HEART FAILURE

Hybrid drugs between nitrates and KATP openers such as nicorandil have a balanced haemodynamic profile of preload and afterload reduction. This effect profile resembles that produced by the combined treatment of isosorbide dinitrate and hydralazine which was used in the V-HeFT studies. In the V-HeFT II study the ACE inhibitor enalapril was superior to isosorbide dinitrate and hydralazine in terms of mortality, whereas the latter combination was superior to enalapril in improving left ventricular function and exercise capacity of the patients. Nicorandil has so far shown favourable haemodynamic actions in heart failure in small short-term clinical studies.

HYPERTENSION

K+ channel openers were originally developed as antihypertensive vasodilators. The best studied drug is pinacidil, which is in clinical use for the treatment of hypertension. This drug is clearly effective in controlling hypertension, but as with other directly acting peripheral vasodilators it causes reflex tachycardia and fluid retention and is not suited to monotherapy. It can be used in combination with β adrenoceptor blockers, diuretics, or ACE inhibitors. It has no adverse effect on blood lipids, glucose tolerance, or insulin secretion. Other K+ channel openers such as levromakalim have been selected for development as antihypertensive agents.

PULMONARY HYPERTENSION

A clinically useful vasodilator for the treatment of pulmonary hypertension should be selective for the pulmonary circulation and produce pulmonary vasodilatation without significant systemic hypotension and cardiodepression. Hypoxic vasoconstriction is a unique feature and probably the most powerful control mechanism of vascular tone in the pulmonary circulation. The essential role of inhibition of K+ channels in this regulatory mechanism raises
the possibility that pharmacological openers of the \( K^+ \) channel involved might be selective pulmonary vasodilators. Although the \( K^+ \) channel subtype involved appears to be different from \( K_{ATP} \) openers of this channel produce pulmonary vasodilatation in vitro and in vivo and inhibit hypoxic pulmonary vaso- constriction in animals.\(^{27}\) Pinacidil and related cyanoguanidine derivatives were more potent relaxants of pulmonary than systemic arteries from the guinea pig.\(^{24}\) So far there are no clinical data available on the effect of \( K^+ \) channel openers in patients with pulmonary hypertension.

**PERIPHERAL VASCULAR DISEASE**

Vasodilators have been unsuccessful in the treatment of intermittent claudication probably because they dilate vessels supplying normally perfused skeletal muscle and thereby divert blood flow away from the ischaemic tissue. In contrast to other vasodilators \( K^+ \) channel openers seem to enhance blood flow to ischaemic skeletal muscle and improve recovery of muscle energy stores in animal models of chronic occlusive arterial disease.\(^{46}\) These beneficial effects were manifested at doses below those affecting systemic blood pressure and may reflect redistribution of blood flow to ischaemic muscle due to selective dilatation of collateral vessels. Hypersensitivity of such vessels to \( K^+ \) channel openers might arise because ischaemic conditions would favour opening of \( K_{ATP} \). Another possible explanation could be differences in nerve supply and populations of \( K^+ \) channels between collaterals and other vessels. Clinical studies on the effect of \( K^+ \) channel openers in patients with peripheral vascular disease have started.

**IMPLICATIONS FOR DIABETIC PATIENTS TREATED WITH SULPHONYLUREA \( K_{ATP} \) BLOCKERS**

Diabetes mellitus is an adverse risk factor in acute myocardial infarction. These patients have a four to five fold higher mortality risk than non-diabetics. The reason why diabetic patients do so badly is unclear. Non-insulin-dependent diabetes mellitus (NIDDM) accounts for 85% of all cases of diabetes and most of these patients are treated with oral antidiabetic sulphonylureas which can block not only pancreatic \( K_{ATP} \) channels but also cardiovascular \( K_{ATP} \) channels. The question arises whether treatment with antidiabetic sulphonylureas is hazardous from a cardiovascular point of view. In a large multicentre trial with an eight year observation period a twofold increase in cardiovascular mortality was observed among patients treated with tolbutamide when compared with placebo or insulin treated patients,\(^{50}\) but the validity of this conclusion has been questioned and is the subject of much debate.\(^{51}\) If the knowledge derived from basic science of the interaction between antidiabetic sulphonylureas and cardiovascular \( K_{ATP} \) channels is clinically relevant the use of sulphonylureas in patients with diabetes should be considered carefully.

**Conclusion**

\( K^+ \) channel openers are a group of novel drugs that target \( K_{ATP} \) channels in the cardiovascular system. This type of \( K^+ \) channel opens during myocardial ischaemia and plays a part in important endogenous protective mechanisms such as 

---

1 Katz AM. Cardiac ion channels. *N Engl J Med* 1993;328:

244-51.


3 Edwards G, Weston AH. Pharmacology of the potassium channel


6 Cavero I, Guillón JM. Pharmacological profile of potassium


Yao Z, Gross GJ. Effects of the K_+ channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-75.


Cook N, Chapman ID. Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma. Cardiovasc Drugs Ther 1993;7 suppl 3:555-63.


K+ channel opening: a new drug principle in cardiovascular medicine.

J. E. Nielsen-Kudsk, S. Boesgaard and J. Aldershvile

*Heart* 1996 76: 109-116
doi: 10.1136/hrt.76.2.109

Updated information and services can be found at:
[http://heart.bmj.com/content/76/2/109.citation](http://heart.bmj.com/content/76/2/109.citation)

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)